Ibex 4 introduces end-to-end breast cancer diagnostic workflows, zero-click immunohistochemistry tools, and expanded laboratory integrations.

Ibex Medical Analytics has unveiled Ibex 4, its next-generation artificial intelligence (AI)-powered pathology, designed to support pathologists facing rising case volumes and increasing diagnostic complexity.

Built on clinically validated algorithms and developed in collaboration with pathology laboratories, Ibex 4 expands the company’s breast cancer diagnostic offering to support end-to-end workflows for biopsies and excisions, from hematoxylin and eosin staining through immunohistochemistry (IHC) analysis.

“Ibex 4 was designed to help pathologists ‘see more and click less,’ focusing their expertise where it matters most,” says Chaim Linhart, chief technology officer at Ibex Medical Analytics, in a release. “One example is Ibex Breast’s ‘zero-click’ IHC quantification and visualization tools, which are particularly useful in identifying a few stained cells and very low levels of HER2 expression, as well as quickly calculating Ki67 proliferation index. Ibex is empowering pathologists to overcome interobserver variability and ensure every patient receives the most precise diagnostic results and insights.”

Expanded Breast Diagnostic Capabilities

Central to the Ibex 4 release is the expansion of the Ibex Breast offering, which now covers the full diagnostic workflow for breast biopsies and excisions. The platform’s IHC tools include quantification and visualization support for HER2, estrogen receptor, progesterone receptor, and Ki67 markers. Ibex Lymph Node, initially available for research use, is slated for broader availability in the near future, according to the company.

The platform also introduces a redesigned user interface, customized reporting capabilities, and advanced workflow integrations intended to increase laboratory efficiency.

Regulatory Status and Industry Presence

Ibex Breast includes solutions that are CE-IVD certified and registered with regulatory bodies including the Medicines and Healthcare products Regulatory Agency in the United Kingdom, the Therapeutic Goods Administration in Australia, the Agência Nacional de Vigilância Sanitária in Brazil, AMAR in Israel, and Swissmedic in Switzerland. One solution holds Food and Drug Administration (FDA) clearance in the United States, while others are designated Research Use Only by the FDA.

The company also recently announced an expansion of its biopharma business, extending its AI-powered product offering into biomarker development, according to the release.

Details on Ibex 4 and live demonstrations will be available at the 115th United States and Canadian Academy of Pathology Annual Meeting in San Antonio, Texas, March 21–26.

ID 176672987 © Alphaspirit | Dreamstime.com

Related Reading: